CDKN2A and glioma: In other work, it was shown that copy number variation (CNV) was more frequent in recurrent tumors and CDKN2A/B loss was significantly enriched in the sample [64], but that study included IDH1/2 mutant glioma, where CDKN2A/B deletion is a marker of tumor progression.